About Cellectis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PRESS RELEASE Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic.

France generalNorth carolinaUnited statesNew yorkPascalyne wilsonArthur strilSosa navarroSecurities exchange commissionAbout cellectisNasdaq global marketEuronext growthPrivate securities litigation reform actAnnual reportInterim chief financial officerLifesci advisors